Metformin News and Research RSS Feed - Metformin News and Research

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.
Diabetes drug metformin can also treat portal hypertension

Diabetes drug metformin can also treat portal hypertension

The diabetes drug metformin continues to expand beyond its treatment for type 2 diabetes. In addition to its potential use in treating age-related health problems, metformin can treat portal hypertension—high blood pressure in the liver resulting from cirrhosis, according to a new study in American Journal of Physiology—Gastrointestinal and Liver Physiology. [More]
Diabetes drug metformin does not stop babies from being born overweight

Diabetes drug metformin does not stop babies from being born overweight

Treating obese pregnant women with a diabetes drug does not stop their babies from being born overweight, a study has found. [More]
Pioglitazone drug significantly decreases risk of dementia

Pioglitazone drug significantly decreases risk of dementia

Patients with type 2 diabetes have a dysfunctional sugar metabolism because the essential hormone insulin does not work effectively. Once the disease reaches an advanced stage, the body stops producing insulin altogether, which means that it has to be administered externally. [More]
Researchers looking to enroll patients in groundbreaking NIH diabetes study

Researchers looking to enroll patients in groundbreaking NIH diabetes study

Maria Gaona has been battling diabetes for eight years. Coupled with a family history of the disease, poor eating habits and no exercise regimen, the 64-year-old faces a lifetime of daily medications to control her disease. Fortunately, in 2014, she enrolled in a groundbreaking national research study that has already helped her control her glucose level, lose 16 pounds and regulate her daily medications. [More]
Combining lifestyle modification with metformin could help women manage polycystic ovary syndrome

Combining lifestyle modification with metformin could help women manage polycystic ovary syndrome

A systematic review publishing today in the journal Human Reproduction Update has found that women who suffer from polycystic ovary syndrome (PCOS) could manage some of the symptoms by combining a change in lifestyle with taking the drug metformin. [More]
Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association. [More]
Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Day in and day out, for years on end, millions of people with diabetes prick their fingers to test their blood sugar level. And many may wonder if all the careful eating, exercise and medication it takes to keep those levels under control is really worth it. [More]
McMaster University researchers identify key protein required to maintain muscle strength during aging

McMaster University researchers identify key protein required to maintain muscle strength during aging

What causes us to lose muscle strength as we age and how exercise can prevent it from happening has never been thoroughly understood, but McMaster University researchers have discovered a key protein required to maintain muscle mass and muscle strength during aging. [More]
Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures. [More]
New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. [More]
Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9. [More]
Metformin can reduce risk of open-angle glaucoma in people with diabetes

Metformin can reduce risk of open-angle glaucoma in people with diabetes

Taking the medication metformin hydrochloride was associated with reduced risk of developing the sight-threatening disease open-angle glaucoma in people with diabetes, according to a study published online by JAMA Ophthalmology. [More]
Treatment outcomes in type 1 diabetes could be improved across all age groups

Treatment outcomes in type 1 diabetes could be improved across all age groups

In a sweeping analysis assessing the current state of diabetes treatment in the U.S., T1D Exchange researchers conclude that there remains considerable room for improving treatment outcomes in type 1 diabetes across all age groups, but especially for adolescents and young adults. [More]

Disease-specific employee-based health plan helps reduce costs of care

People with diabetes who enroll in a health plan tailored to their medical condition are more likely to stick to their medication and actively take charge of their own health care. These are among the findings of a study into the effectiveness of the Diabetes Health Plan, the first disease-specific health plan in the United States for patients with diabetes and pre-diabetes. [More]
IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type 2 diabetes. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapies. [More]
Common diabetes medication causes intersex in fish

Common diabetes medication causes intersex in fish

A medication commonly taken for Type II diabetes, which is being found in freshwater systems worldwide, has been shown to cause intersex in fish -male fish that produce eggs. [More]
Study supports use of vitamin E as effective treatment for NASH

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis. [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Many children who require insulin treatment on diagnosis with Type 2 diabetes can be weaned off the medication, show findings from the run-in phase of the Treatment Options for Type 2 Diabetes in Adolescents and Youth study. [More]
Vitamin D3 and metformin show promising results in preventing colorectal cancer

Vitamin D3 and metformin show promising results in preventing colorectal cancer

The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible. [More]
Advertisement
Advertisement